In a randomized , double-blind trial involving 135 patients with severe eosinophilic asthma , we compared the glucocorticoid-sparing effect of mepolizumab ( at a dose of 100 mg ) with that of placebo administered subcutaneously every 4 weeks for 20 weeks .